OncoMatch/Clinical Trials/NCT06363994
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Is NCT06363994 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Orelabrutinib and Bendamustine for mantle cell lymphoma.
Treatment: Orelabrutinib · Bendamustine · Rituximab — Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CCND1 overexpression
expression of Cyclin D1
Required: IGH t(11;14) chromosomal translocation
t (11; 14) chromosomal translocation
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06363994 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CCND1?
Yes, CCND1 overexpression is a required biomarker for enrollment.
Does this trial require IGH?
Yes, IGH t(11;14) chromosomal translocation is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages